Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma

Sponsor
Arrowhead Pharmaceuticals
Study ID
NCT07241546
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • ARO-RAGE — DRUG
    Inhalation of nebulized solution
  • Placebo — DRUG
    Calculated volume to match active treatment by inhalation of nebulized solution

Study Details

The purpose of this study is to evaluate the impact of inhaled ARO-RAGE on the late asthmatic response (LAR) following an inhaled allergen challenge in participants with mild atopic asthma.

Key Dates

First listed
Nov 21, 2025
Start date
Mar 30, 2026
Status verified
Jun 2026
Primary completion
Dec 31, 2027
Completion
Apr 30, 2028

Study Design

Enrollment
36 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: ARO-RAGE
    ARO-RAGE inhalation
  • Placebo Comparator: Placebo
    Normal saline (0.9%)

Primary Outcome Measure

Change from Baseline Over Time in Maximum Area of Reactance [ Time Frame: Baseline through Day 58 ]

Central Contacts

Find similar trials

Nationwide
Asthma trialsPulmonology trialsLung disease trials

Related Studies